Unicycive Therapeutics Expands ATM Offering to $150M Ahead of Key FDA Decision
UNCY sits 87% above its 52-week low of $3.71 on elevated volume (2.0× avg).
Summary
Unicycive Therapeutics expanded its ATM stock offering program by $50 million to a total of $150 million, securing more capital ahead of a crucial FDA decision for its OLC drug.
Key Events · Financing and Capital Events · UNCY
-
ATM Program Expansion
The company amended its Sales Agreement to increase the aggregate offering price of its At-The-Market (ATM) program from $100 million to $150 million.
-
Concurrent S-3 Filing
This amendment is in connection with a Shelf Registration Statement on Form S-3 filed concurrently, allowing the sale of up to $50 million in common stock through the ATM offering.
-
Liquidity for FDA Decision
The capital raise provides essential liquidity as the company awaits a critical FDA PDUFA date of June 29, 2026, for its OLC drug.
Analysis · UNCY · Life Sciences
Unicycive Therapeutics increased its At-The-Market (ATM) offering program by $50 million, raising the total potential offering to $150 million. This move provides additional capital runway for the company, which has been actively utilizing dilutive offerings to secure liquidity. The timing is critical as the company approaches a PDUFA date of June 29, 2026, for its OLC drug, making access to capital essential for operations and potential commercialization efforts.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UNCY was trading at $6.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $184.8M. The 52-week trading range was $3.71 to $11.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.